Zhirong Lin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Zhirong Lin has a total of 57 co-authors. Here are the top co-authors by number of shared publications:
Shunrong Luo
Xiamen Eye Center and Eye Institute of Xiamen University, School of Medicine, Xiamen, China
6 shared publicationsXianwen Xiao
Xiamen Eye Center and Eye Institute of Xiamen University, School of Medicine, Xiamen, China
6 shared publicationsXie Fang
Xiamen Eye Center and Eye Institute of Xiamen University, School of Medicine, Xiamen, China
6 shared publicationsHuan He
Eye Institute and Affiliated Xiamen Eye Center of Xiamen University, School of Medicine, Xiamen University, Xiamen, China; Xiamen Municipal Clinical Research Center for Eye Diseases, Xiamen, China; Xiamen Municipal Key Laboratory of Ophthalmology, Xiamen, China
5 shared publicationsHuping Wu
Xiamen Eye Center and Eye Institute of Xiamen University, School of Medicine, Xiamen, China
5 shared publicationsZhiwen Xie
Xiamen Eye Center and Eye Institute of Xiamen University, School of Medicine, Xiamen, China
5 shared publications
Latest Publications
- 9 February 2026
- Published by Elsevier in Experimental Eye Research
- Vol. 266, 110911
Decreased corneal biomechanical stability and structural integrity in PPAR-α knockout mice
- 9 February 2026
- Published by Elsevier in Experimental Eye Research
- Vol. 266, 110911
Decreased corneal biomechanical stability and structural integrity in PPAR-α knockout mice
- Open Access
- 27 October 2025
- Published by Springer Nature in BMC Ophthalmology
- Vol. 25 (1) , 1-11
Topical 5-fluorouracil 1% versus surgical removal as a primary treatment modality for ocular surface squamous neoplasia: a comparison of recurrences and side effects
To compare the efficacy and safety of topical 5-fluorouracil (5-FU) 1% eye drops versus surgical removal as a primary treatment modality for ocular surface squamous neoplasia (OSSN). This retrospective cohort study included 11 patients who received 5-FU 1% (5-FU group) and 14 patients who received surgical removal (surgery group) as a primary therapy for OSSN in an ophthalmic hospital from 2018 to 2023. The primary outcome measure was the comparative incidence of OSSN recurrence between the two therapeutic modalities. The secondary outcome was the frequency of side effects with each therapy. No significant differences were found in demographic characteristics, with comparable mean ages (5-FU group: 58.6 ± 22.7 vs. surgery group: 63.1 ± 14.4 years, p = 0.55) and gender distributions (male: 81.8% vs. 78.6%, p = 1.00). The recurrence rate was 18.2% in the 5-FU group versus 14.3% in the surgery group (p > 0.99). There was no statistically significant difference in the recurrence rate between the 5-FU and surgery groups. Patients were treated a median of 3 cycles (range 1–9) of topical 5-FU eye drops in the 5-FU group. Treatment-related ocular symptoms were reported in 45.5% (5/11) of patients in the 5-FU group, while a 57.1% (8/14) incidence of side effects in the surgical group. The mean follow-up duration for the 5-FU group was 28.4 ± 14.8 months, while that for the surgery group was 36.4 ± 20.3 months. The side effects of the two groups of patients were similar, mainly including redness, irritation, pain, and so on. Limbal stem cell deficiency, symblepharon, and systemic symptoms were not observed in either the 5-FU or surgery groups. Both 5-FU and surgical removal are effective and present a good security profile as primary therapies for OSSN. The two treatment modalities have no significant difference in the frequency of side effects or the time interval to recurrence.
- 27 October 2025
- Published by Springer Nature in BMC Ophthalmology
- Vol. 25 (1) , 1-11
Open AccessTopical 5-fluorouracil 1% versus surgical removal as a primary treatment modality for ocular surface squamous neoplasia: a comparison of recurrences and side effects
To compare the efficacy and safety of topical 5-fluorouracil (5-FU) 1% eye drops versus surgical removal as a primary treatment modality for ocular surface squamous neoplasia (OSSN). This retrospective cohort study included 11 patients who received 5-FU 1% (5-FU group) and 14 patients who received surgical removal (surgery group) as a primary therapy for OSSN in an ophthalmic hospital from 2018 to 2023. The primary outcome measure was the comparative incidence of OSSN recurrence between the two therapeutic modalities. The secondary outcome was the frequency of side effects with each therapy. No significant differences were found in demographic characteristics, with comparable mean ages (5-FU group: 58.6 ± 22.7 vs. surgery group: 63.1 ± 14.4 years, p = 0.55) and gender distributions (male: 81.8% vs. 78.6%, p = 1.00). The recurrence rate was 18.2% in the 5-FU group versus 14.3% in the surgery group (p > 0.99). There was no statistically significant difference in the recurrence rate between the 5-FU and surgery groups. Patients were treated a median of 3 cycles (range 1–9) of topical 5-FU eye drops in the 5-FU group. Treatment-related ocular symptoms were reported in 45.5% (5/11) of patients in the 5-FU group, while a 57.1% (8/14) incidence of side effects in the surgical group. The mean follow-up duration for the 5-FU group was 28.4 ± 14.8 months, while that for the surgery group was 36.4 ± 20.3 months. The side effects of the two groups of patients were similar, mainly including redness, irritation, pain, and so on. Limbal stem cell deficiency, symblepharon, and systemic symptoms were not observed in either the 5-FU or surgery groups. Both 5-FU and surgical removal are effective and present a good security profile as primary therapies for OSSN. The two treatment modalities have no significant difference in the frequency of side effects or the time interval to recurrence.
- Open Access
- 17 July 2025
- Published by Elsevier in Materials Today Bio
- Vol. 34, 102110
A bioequivalent cornea cross-linking method using photo-initiators LAP and visible light
- 17 July 2025
- Published by Elsevier in Materials Today Bio
- Vol. 34, 102110
Open AccessA bioequivalent cornea cross-linking method using photo-initiators LAP and visible light
- 24 April 2025
- Published by SAGE Publications in European Journal of Ophthalmology
- Vol. 35 (5) , 1921-1931
Ocular surface squamous neoplasia: Growth, diagnosis, and treatment
Background: Ocular surface squamous neoplasia (OSSN) is the most common malignancy of the ocular surface, often presenting as a non-pigmented lesion with atypical squamous epithelialization. It is usually asymptomatic and can be confused with benign conditions such as pterygium or conjunctival cysts. If untreated, OSSN may progress to invasive squamous cell carcinoma, causing vision loss or metastasis. The gold standard for diagnosing OSSN is histopathological examination after tumor resection. However, there are still unresolved issues in the clinical management of treatment. Main text: In this review, we have discussed the clinical characteristics, diagnostic techniques, and treatment options for OSSN. OSSN occurs due to changes in the living environment and ocular surface state. It starts as a benign squamous epithelial tumor, which can progress to atypical intraepithelial neoplasia and eventually turn into invasive squamous cell carcinoma. The postoperative pathological histology also shows a corresponding degree of differentiation. Various diagnostic techniques, such as diagnostic imaging, cell biology, and molecular biology, are emerging as valuable tools for distinguishing OSSN. Although surgical resection is the primary treatment for OSSN, drug therapy can also be applied for better management of OSSN treatment. Conclusion: Accurately diagnosing OSSN requires advanced examination techniques before and after operation. This is crucial for healthcare professionals to evaluate and treat the condition effectively. Based on our clinical expertise, administering drug treatment before or after surgical resection may serve as a comprehensive and effective management approach for OSSN. This research holds immense potential for the future of personalized and precise medical care.
- 24 April 2025
- Published by SAGE Publications in European Journal of Ophthalmology
- Vol. 35 (5) , 1921-1931
Ocular surface squamous neoplasia: Growth, diagnosis, and treatment
Background: Ocular surface squamous neoplasia (OSSN) is the most common malignancy of the ocular surface, often presenting as a non-pigmented lesion with atypical squamous epithelialization. It is usually asymptomatic and can be confused with benign conditions such as pterygium or conjunctival cysts. If untreated, OSSN may progress to invasive squamous cell carcinoma, causing vision loss or metastasis. The gold standard for diagnosing OSSN is histopathological examination after tumor resection. However, there are still unresolved issues in the clinical management of treatment. Main text: In this review, we have discussed the clinical characteristics, diagnostic techniques, and treatment options for OSSN. OSSN occurs due to changes in the living environment and ocular surface state. It starts as a benign squamous epithelial tumor, which can progress to atypical intraepithelial neoplasia and eventually turn into invasive squamous cell carcinoma. The postoperative pathological histology also shows a corresponding degree of differentiation. Various diagnostic techniques, such as diagnostic imaging, cell biology, and molecular biology, are emerging as valuable tools for distinguishing OSSN. Although surgical resection is the primary treatment for OSSN, drug therapy can also be applied for better management of OSSN treatment. Conclusion: Accurately diagnosing OSSN requires advanced examination techniques before and after operation. This is crucial for healthcare professionals to evaluate and treat the condition effectively. Based on our clinical expertise, administering drug treatment before or after surgical resection may serve as a comprehensive and effective management approach for OSSN. This research holds immense potential for the future of personalized and precise medical care.
- 3 November 2023
- Published by Taylor & Francis in Current Eye Research
- Vol. 49 (2) , 119-130
Clinical and Morphological in Vivo Confocal Microscopy Findings following a Modified Biphasic Higher Fluence Transepithelial Corneal Crosslinking
Purpose To compare the refractive efficacy and morphological changes in the cornea following a novel biphasic higher fluence transepithelial corneal crosslinking (BI-TE-CXL) and transepithelial corneal crosslinking (TE-CXL) in adults keratoconus.Methods Patients with progressive keratoconus who required corneal crosslinking were assigned to the BI-TE-CXL group (32 eyes, phase 1: 7.2 J/cm2 for 5 minutes and 20 seconds of pulsed-light exposure, KXL, Glaukos-Avedro; phase 2: 3.6 J/cm2 for 6 minutes and 40 seconds of continuous light exposure at the front curvature apex with a 6 mm diameter light spot, UVX-2000, IROC) or the TE-CXL group (32 eyes, uniform 7.2 J/cm2 for 5 minutes and 20 seconds of pulsed-light exposure, KXL, Glaukos-Avedro). Uncorrected distance visual acuity (UDVA), corrected distance visual acuity (CDVA), corneal fluorescein staining (CFS), corneal topography, anterior segment optical coherence tomography (AS-OCT), and in vivo corneal confocal microscopy (IVCM) were performed 3, 6, 12 and 24 months after surgery.Results The CFS scores in the BI-TE-CXL group were significantly higher than those in the TE-CXL group on the first two days after surgery (P < 0.001). The Kmax (at 12 and 24 months) and CDVA (logMAR) were significantly lower in the BI-TE-CXL group than those in the TE-CXL group (P < 0.05). The corneal demarcation line under AS-OCT was visible in 81.3% of patients in the BI-TE-CXL group and 15.6% in the TE-CXL group. The depth of demarcation line under IVCM was significantly deeper in the BI-TE-CXL group (248.3 ± 25.0μm) than that of the TE-CXL group (136.5 ± 15.6μm) in the central cornea (P < 0.001). The cross-linked collagen structures in the central cornea were still present after 12 months in the BI-TE-CXL group. No significant difference in sub-basal nerve density between the two groups (P > 0.05).Conclusions Following BI-TE-CXL, CDVA was significantly improved, accompanied by deeper demarcation line depth and persistent crosslinked structures in the central corneal stroma.
- 3 November 2023
- Published by Taylor & Francis in Current Eye Research
- Vol. 49 (2) , 119-130
Clinical and Morphological in Vivo Confocal Microscopy Findings following a Modified Biphasic Higher Fluence Transepithelial Corneal Crosslinking
Purpose To compare the refractive efficacy and morphological changes in the cornea following a novel biphasic higher fluence transepithelial corneal crosslinking (BI-TE-CXL) and transepithelial corneal crosslinking (TE-CXL) in adults keratoconus.Methods Patients with progressive keratoconus who required corneal crosslinking were assigned to the BI-TE-CXL group (32 eyes, phase 1: 7.2 J/cm2 for 5 minutes and 20 seconds of pulsed-light exposure, KXL, Glaukos-Avedro; phase 2: 3.6 J/cm2 for 6 minutes and 40 seconds of continuous light exposure at the front curvature apex with a 6 mm diameter light spot, UVX-2000, IROC) or the TE-CXL group (32 eyes, uniform 7.2 J/cm2 for 5 minutes and 20 seconds of pulsed-light exposure, KXL, Glaukos-Avedro). Uncorrected distance visual acuity (UDVA), corrected distance visual acuity (CDVA), corneal fluorescein staining (CFS), corneal topography, anterior segment optical coherence tomography (AS-OCT), and in vivo corneal confocal microscopy (IVCM) were performed 3, 6, 12 and 24 months after surgery.Results The CFS scores in the BI-TE-CXL group were significantly higher than those in the TE-CXL group on the first two days after surgery (P < 0.001). The Kmax (at 12 and 24 months) and CDVA (logMAR) were significantly lower in the BI-TE-CXL group than those in the TE-CXL group (P < 0.05). The corneal demarcation line under AS-OCT was visible in 81.3% of patients in the BI-TE-CXL group and 15.6% in the TE-CXL group. The depth of demarcation line under IVCM was significantly deeper in the BI-TE-CXL group (248.3 ± 25.0μm) than that of the TE-CXL group (136.5 ± 15.6μm) in the central cornea (P < 0.001). The cross-linked collagen structures in the central cornea were still present after 12 months in the BI-TE-CXL group. No significant difference in sub-basal nerve density between the two groups (P > 0.05).Conclusions Following BI-TE-CXL, CDVA was significantly improved, accompanied by deeper demarcation line depth and persistent crosslinked structures in the central corneal stroma.
- 29 July 2022
- Published by Springer Nature in Naunyn-Schmiedeberg's Archives of Pharmacology
- Vol. 395 (11) , 1373-1385
GDH promotes isoprenaline-induced cardiac hypertrophy by activating mTOR signaling via elevation of α-ketoglutarate level
Numerous studies reveal that metabolism dysfunction contributes to the development of pathological cardiac hypertrophy. While the abnormal lipid and glucose utilization in cardiomyocytes responding to hypertrophic stimuli have been extensively studied, the alteration and implication of glutaminolysis are rarely discussed. In the present work, we provide the first evidence that glutamate dehydrogenase (GDH), an enzyme that catalyzes conversion of glutamate into ɑ-ketoglutarate (AKG), participates in isoprenaline (ISO)-induced cardiac hypertrophy through activating mammalian target of rapamycin (mTOR) signaling. The expression and activity of GDH were enhanced in cultured cardiomyocytes and rat hearts following ISO treatment. Overexpression of GDH, but not its enzymatically inactive mutant, provoked cardiac hypertrophy. In contrast, GDH knockdown could relieve ISO-triggered hypertrophic responses. The intracellular AKG level was elevated by ISO or GDH overexpression, which led to increased phosphorylation of mTOR and downstream effector ribosomal protein S6 kinase (S6K). Exogenous supplement of AKG also resulted in mTOR activation and cardiomyocyte hypertrophy. However, incubation with rapamycin, an mTOR inhibitor, attenuated hypertrophic responses in cardiomyocytes. Furthermore, GDH silencing protected rats from ISO-induced cardiac hypertrophy. These findings give a further insight into the role of GDH in cardiac hypertrophy and suggest it as a potential target for hypertrophy-related cardiomyopathy.
- 29 July 2022
- Published by Springer Nature in Naunyn-Schmiedeberg's Archives of Pharmacology
- Vol. 395 (11) , 1373-1385
GDH promotes isoprenaline-induced cardiac hypertrophy by activating mTOR signaling via elevation of α-ketoglutarate level
Numerous studies reveal that metabolism dysfunction contributes to the development of pathological cardiac hypertrophy. While the abnormal lipid and glucose utilization in cardiomyocytes responding to hypertrophic stimuli have been extensively studied, the alteration and implication of glutaminolysis are rarely discussed. In the present work, we provide the first evidence that glutamate dehydrogenase (GDH), an enzyme that catalyzes conversion of glutamate into ɑ-ketoglutarate (AKG), participates in isoprenaline (ISO)-induced cardiac hypertrophy through activating mammalian target of rapamycin (mTOR) signaling. The expression and activity of GDH were enhanced in cultured cardiomyocytes and rat hearts following ISO treatment. Overexpression of GDH, but not its enzymatically inactive mutant, provoked cardiac hypertrophy. In contrast, GDH knockdown could relieve ISO-triggered hypertrophic responses. The intracellular AKG level was elevated by ISO or GDH overexpression, which led to increased phosphorylation of mTOR and downstream effector ribosomal protein S6 kinase (S6K). Exogenous supplement of AKG also resulted in mTOR activation and cardiomyocyte hypertrophy. However, incubation with rapamycin, an mTOR inhibitor, attenuated hypertrophic responses in cardiomyocytes. Furthermore, GDH silencing protected rats from ISO-induced cardiac hypertrophy. These findings give a further insight into the role of GDH in cardiac hypertrophy and suggest it as a potential target for hypertrophy-related cardiomyopathy.
- Open Access
- 26 May 2022
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 9, 762730
Ovalbumin-Induced Allergic Inflammation Diminishes Cross-Linked Collagen Structures in an Experimental Rabbit Model of Corneal Cross-Linking
Background: Allergic conjunctivitis (AC) is one of the reported potential risk factors of progression in keratoconus patients after corneal cross-linking surgery; however, the causal relationship is still inconclusive. Recent studies have indicated that various inflammatory cytokines play a vital role in the development of primary keratoconus. It is still unclear whether these inflammatory mediators also trigger CXL failures. This study aimed to investigate the impact of AC on the rabbit corneas after trans-epithelial corneal cross-linking (TCXL).Methods: A total of six rabbits were kept untreated as the normal control (NC) group. A total of 18 rabbits were treated by TCXL and divided into three groups (six in each group), namely, no treatment (TCXL group); induction of AC (TCXL + AC group); and induction of AC plus topical prednisolone acetate (TCXL + AC + PA group), according to additional treatment. AC was induced by topical application of ovalbumin after intraperitoneal pre-sensitization with ovalbumin. Rabbits were evaluated by slit lamp, in vivo laser scanning confocal microscopy, anterior segment optical coherence tomography, and measurement of corneal biomechanics. The cornea specimens were collected for the transmission electron microscope, the collagenase I digestion test, and PCR assay for TNF-α, IL-6, IL-1β, matrix metalloproteinase 9 (MMP-9), lysyl oxidase (LOX), and tissue inhibitor of metalloproteinases 1 (TIMP-1) on the day (D) 28.Results: On D28, the TNF-α, IL-6, IL-1β, MMP-9, and LOX levels were significantly increased while the TIMP-1 was decreased in the TCXL + AC group when compared with the TCXL and TCXL + AC + PA groups. In vivo confocal microscopy revealed that at a depth of 150–210 μm, a trabecular patterned hyperdense structure surrounded by elongated needle-like processes could be observed in the TCXL and TCXL + AC + PA groups, but hardly seen in the TCXL + AC group. The demarcation lines were indistinct and blurred in the TCXL + AC group. An electron microscope demonstrated less interlacing fibril lamellae and higher interfibrillar spacing in the TCXL + AC group. The stability of corneal biomechanics and resistance to collagenase were decreased in the TCXL + AC group.Conclusion: The corneal microstructures induced by TCXL and biomechanical stability were diminished in rabbits with AC but could be maintained by topical anti-inflammatory treatment. Our results supported the causal relationship between altered cytokine profiles and corneal microstructure after primary corneal cross-linking.
- 26 May 2022
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 9, 762730
Open AccessOvalbumin-Induced Allergic Inflammation Diminishes Cross-Linked Collagen Structures in an Experimental Rabbit Model of Corneal Cross-Linking
Background: Allergic conjunctivitis (AC) is one of the reported potential risk factors of progression in keratoconus patients after corneal cross-linking surgery; however, the causal relationship is still inconclusive. Recent studies have indicated that various inflammatory cytokines play a vital role in the development of primary keratoconus. It is still unclear whether these inflammatory mediators also trigger CXL failures. This study aimed to investigate the impact of AC on the rabbit corneas after trans-epithelial corneal cross-linking (TCXL).Methods: A total of six rabbits were kept untreated as the normal control (NC) group. A total of 18 rabbits were treated by TCXL and divided into three groups (six in each group), namely, no treatment (TCXL group); induction of AC (TCXL + AC group); and induction of AC plus topical prednisolone acetate (TCXL + AC + PA group), according to additional treatment. AC was induced by topical application of ovalbumin after intraperitoneal pre-sensitization with ovalbumin. Rabbits were evaluated by slit lamp, in vivo laser scanning confocal microscopy, anterior segment optical coherence tomography, and measurement of corneal biomechanics. The cornea specimens were collected for the transmission electron microscope, the collagenase I digestion test, and PCR assay for TNF-α, IL-6, IL-1β, matrix metalloproteinase 9 (MMP-9), lysyl oxidase (LOX), and tissue inhibitor of metalloproteinases 1 (TIMP-1) on the day (D) 28.Results: On D28, the TNF-α, IL-6, IL-1β, MMP-9, and LOX levels were significantly increased while the TIMP-1 was decreased in the TCXL + AC group when compared with the TCXL and TCXL + AC + PA groups. In vivo confocal microscopy revealed that at a depth of 150–210 μm, a trabecular patterned hyperdense structure surrounded by elongated needle-like processes could be observed in the TCXL and TCXL + AC + PA groups, but hardly seen in the TCXL + AC group. The demarcation lines were indistinct and blurred in the TCXL + AC group. An electron microscope demonstrated less interlacing fibril lamellae and higher interfibrillar spacing in the TCXL + AC group. The stability of corneal biomechanics and resistance to collagenase were decreased in the TCXL + AC group.Conclusion: The corneal microstructures induced by TCXL and biomechanical stability were diminished in rabbits with AC but could be maintained by topical anti-inflammatory treatment. Our results supported the causal relationship between altered cytokine profiles and corneal microstructure after primary corneal cross-linking.
- Open Access
- 14 February 2022
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 13, 798436
PKC-ζ Aggravates Doxorubicin-Induced Cardiotoxicity by Inhibiting Wnt/β-Catenin Signaling
Doxorubicin (Dox) is a chemotherapeutic drug used to treat a wide range of cancers, but its clinical application is limited due to its cardiotoxicity. Protein kinase C-ζ (PKC-ζ) is a serine/threonine kinase belonging to atypical protein kinase C (PKC) subfamily, and is activated by its phosphorylation. We and others have reported that PKC-ζ induced cardiac hypertrophy by activating the inflammatory signaling pathway. This study focused on whether PKC-ζ played an important role in Dox-induced cardiotoxicity. We found that PKC-ζ phosphorylation was increased by Dox treatment in vivo and in vitro. PKC-ζ overexpression exacerbated Dox-induced cardiotoxicity. Conversely, knockdown of PKC-ζ by siRNA relieved Dox-induced cardiotoxicity. Similar results were observed when PKC-ζ enzyme activity was inhibited by its pseudosubstrate inhibitor, Myristoylated. PKC-ζ interacted with β-catenin and inhibited Wnt/β-catenin signaling pathway. Activation of Wnt/β-catenin signaling by LiCl protected against Dox-induced cardiotoxicity. The Wnt/β-catenin inhibitor XAV-939 aggravated Dox-caused decline of β-catenin and cardiomyocyte apoptosis and mitochondrial damage. Moreover, activation of Wnt/β-catenin suppressed aggravation of Dox-induced cardiotoxicity due to PKC-ζ overexpression. Taken together, our study revealed that inhibition of PKC-ζ activity was a potential cardioprotective approach to preventing Dox-induced cardiac injury.
- 14 February 2022
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 13, 798436
Open AccessPKC-ζ Aggravates Doxorubicin-Induced Cardiotoxicity by Inhibiting Wnt/β-Catenin Signaling
Doxorubicin (Dox) is a chemotherapeutic drug used to treat a wide range of cancers, but its clinical application is limited due to its cardiotoxicity. Protein kinase C-ζ (PKC-ζ) is a serine/threonine kinase belonging to atypical protein kinase C (PKC) subfamily, and is activated by its phosphorylation. We and others have reported that PKC-ζ induced cardiac hypertrophy by activating the inflammatory signaling pathway. This study focused on whether PKC-ζ played an important role in Dox-induced cardiotoxicity. We found that PKC-ζ phosphorylation was increased by Dox treatment in vivo and in vitro. PKC-ζ overexpression exacerbated Dox-induced cardiotoxicity. Conversely, knockdown of PKC-ζ by siRNA relieved Dox-induced cardiotoxicity. Similar results were observed when PKC-ζ enzyme activity was inhibited by its pseudosubstrate inhibitor, Myristoylated. PKC-ζ interacted with β-catenin and inhibited Wnt/β-catenin signaling pathway. Activation of Wnt/β-catenin signaling by LiCl protected against Dox-induced cardiotoxicity. The Wnt/β-catenin inhibitor XAV-939 aggravated Dox-caused decline of β-catenin and cardiomyocyte apoptosis and mitochondrial damage. Moreover, activation of Wnt/β-catenin suppressed aggravation of Dox-induced cardiotoxicity due to PKC-ζ overexpression. Taken together, our study revealed that inhibition of PKC-ζ activity was a potential cardioprotective approach to preventing Dox-induced cardiac injury.
- Open Access
- 7 January 2021
- Published by Springer Nature in Eye
- Vol. 35 (11) , 3020-3027
Safety and efficacy of repeated crosslinking assisted by transepithelial double-cycle iontophoresis in keratoconus progression after primary corneal crosslinking
Objectives: To evaluate the safety and efficacy of repeated corneal collagen crosslinking assisted by transepithelial double-cycle iontophoresis (DI-CXL) in the management of keratoconus progression after primary CXL.Methods: A retrospective analysis was conducted in the patients who underwent repeated CXL between 2016 and 2018. These patients were treated with DI-CXL if keratoconus progression was confirmed after primary CXL. Scoring of ocular pain and corneal epithelial damage, visual acuity, corneal tomography, in vivo corneal confocal microscopy (IVCM) was performed before and at 3, 6, 12, and 24 months after DI-CXL.Results: Overall, 21 eyes of 12 patients (mean age 17.3 ± 1.9 years) were included in this study. Before DI-CXL, an average increase of 4.26 D inKmaxwas detected in these patients with a mean follow-up interval of (23.0 ± 13.7) months. After DI-CXL, corneal epithelial damage rapidly recovered within days. Visual acuity remained unchanged with follow-up of 24 months. When compared to baseline, significant decreases were observed inKmax(at 3 months) and K2 (at 3 and 6 months) after DI-CXL. Corneal thickness of thinnest point significantly decreased at 3 months postoperatively. When compared to baseline, no significant differences were found in any of the refractive or tomographic parameters at 12 and 24 months. IVCM revealed trabecular patterned hyperdense tissues after DI-CXL in the anterior stroma at the depth of 200 μm or more. No corneal infiltration or persistent epithelial defect was recorded after DI-CXL.Conclusion: DI-CXL is safe and effective as a good alternative in stabilizing keratoconus progression after primary CXL.
- 7 January 2021
- Published by Springer Nature in Eye
- Vol. 35 (11) , 3020-3027
Open AccessSafety and efficacy of repeated crosslinking assisted by transepithelial double-cycle iontophoresis in keratoconus progression after primary corneal crosslinking
Objectives: To evaluate the safety and efficacy of repeated corneal collagen crosslinking assisted by transepithelial double-cycle iontophoresis (DI-CXL) in the management of keratoconus progression after primary CXL.Methods: A retrospective analysis was conducted in the patients who underwent repeated CXL between 2016 and 2018. These patients were treated with DI-CXL if keratoconus progression was confirmed after primary CXL. Scoring of ocular pain and corneal epithelial damage, visual acuity, corneal tomography, in vivo corneal confocal microscopy (IVCM) was performed before and at 3, 6, 12, and 24 months after DI-CXL.Results: Overall, 21 eyes of 12 patients (mean age 17.3 ± 1.9 years) were included in this study. Before DI-CXL, an average increase of 4.26 D inKmaxwas detected in these patients with a mean follow-up interval of (23.0 ± 13.7) months. After DI-CXL, corneal epithelial damage rapidly recovered within days. Visual acuity remained unchanged with follow-up of 24 months. When compared to baseline, significant decreases were observed inKmax(at 3 months) and K2 (at 3 and 6 months) after DI-CXL. Corneal thickness of thinnest point significantly decreased at 3 months postoperatively. When compared to baseline, no significant differences were found in any of the refractive or tomographic parameters at 12 and 24 months. IVCM revealed trabecular patterned hyperdense tissues after DI-CXL in the anterior stroma at the depth of 200 μm or more. No corneal infiltration or persistent epithelial defect was recorded after DI-CXL.Conclusion: DI-CXL is safe and effective as a good alternative in stabilizing keratoconus progression after primary CXL.
- Open Access
- 29 July 2020
- Published by Springer Nature in Graefe's Archive for Clinical and Experimental Ophthalmology
- Vol. 259 (1) , 239-246
Transepithelial corneal cross-linking assisted by two continuous cycles of iontophoresis for progressive keratoconus in adults: retrospective 5-year analysis
Purpose: The aim of this study is to compare the long-term effects of transepithelial corneal crosslinking with two continuous cycles of iontophoresis (EI-CXL) and conventional corneal crosslinking (C-CXL) in adults with progressive keratoconus. Methods: A retrospective analysis was conducted in adults who underwent C-CXL or EI-CXL between 2013 and 2015. Visual acuity, corneal tomography, anterior segment optical coherence tomography, in vivo corneal confocal microscopy (IVCM), and endothelial cell count (ECC) were performed preoperatively and 5 years postoperatively. Results: Sixty-eight patients with a mean age of (24.3 ± 3.8) years were included, 34 for each group. After CXL, UCVA or BCVA remained stable, while the spherical diopter, cylinder diopter, spherical equivalent, and Kmax significantly decreased at 1, 2, and 3 years in both groups than baseline (P < 0.05). No significant differences were found in any refractive or tomographic parameters as well as the minimal corneal thickness between groups during follow-up. At 5 years, Kmax was slightly higher in EI-CXL group (58.16 ± 6.28) than that of C-CXL group (57.46 ± 4.98). At 3 and 5 years, the minimal corneal thickness in C-CXL group was still significantly lower than baseline (P < 0.05). IVCM demonstrated the demarcation zone at a mean depth of (302.0 ± 41.7) μm after C-CXL, and at (251.2 ± 28.1) μm after EI-CXL (P < 0.001). Keratocyte repopulation was detectable at all follow-up timepoint in both groups. Postoperative complications including progression were recorded in 6 patients (11.7%) after C-CXL and 3 patients (8.8%) after EI-CXL. ECC remained stable in both groups. Conclusion: EI-CXL showed approximate efficacy with C-CXL in stabilizing progressive keratoconus in adults. EI-CXL has the potential to be a preferable transepithelial protocol.
- 29 July 2020
- Published by Springer Nature in Graefe's Archive for Clinical and Experimental Ophthalmology
- Vol. 259 (1) , 239-246
Open AccessTransepithelial corneal cross-linking assisted by two continuous cycles of iontophoresis for progressive keratoconus in adults: retrospective 5-year analysis
Purpose: The aim of this study is to compare the long-term effects of transepithelial corneal crosslinking with two continuous cycles of iontophoresis (EI-CXL) and conventional corneal crosslinking (C-CXL) in adults with progressive keratoconus. Methods: A retrospective analysis was conducted in adults who underwent C-CXL or EI-CXL between 2013 and 2015. Visual acuity, corneal tomography, anterior segment optical coherence tomography, in vivo corneal confocal microscopy (IVCM), and endothelial cell count (ECC) were performed preoperatively and 5 years postoperatively. Results: Sixty-eight patients with a mean age of (24.3 ± 3.8) years were included, 34 for each group. After CXL, UCVA or BCVA remained stable, while the spherical diopter, cylinder diopter, spherical equivalent, and Kmax significantly decreased at 1, 2, and 3 years in both groups than baseline (P < 0.05). No significant differences were found in any refractive or tomographic parameters as well as the minimal corneal thickness between groups during follow-up. At 5 years, Kmax was slightly higher in EI-CXL group (58.16 ± 6.28) than that of C-CXL group (57.46 ± 4.98). At 3 and 5 years, the minimal corneal thickness in C-CXL group was still significantly lower than baseline (P < 0.05). IVCM demonstrated the demarcation zone at a mean depth of (302.0 ± 41.7) μm after C-CXL, and at (251.2 ± 28.1) μm after EI-CXL (P < 0.001). Keratocyte repopulation was detectable at all follow-up timepoint in both groups. Postoperative complications including progression were recorded in 6 patients (11.7%) after C-CXL and 3 patients (8.8%) after EI-CXL. ECC remained stable in both groups. Conclusion: EI-CXL showed approximate efficacy with C-CXL in stabilizing progressive keratoconus in adults. EI-CXL has the potential to be a preferable transepithelial protocol.